Why Medtronic plc (MDT) stock moved
Medtronic plc (MDT) shares fell 1.0% to $87.09 as of October 6, 2026, a modest decline from the prior close of $87.97. BestStocks flagged the session as a major change for MDT. The move is tied to company news. Below, we break down what changed for MDT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Medtronic obtained Category I CPT codes for Altaviva and Symplicity Spyral systems for incontinence and hypertension. Category I codes enable broader reimbursement coverage, reducing adoption barriers and expanding addressable markets for both devices.
What it means for Medtronic plc investors
For Medtronic plc investors, the recent signals add up to a bearish shift. On the constructive side: Medtronic plc (MDT) moved +5.04% from $79.20 to $83.19 on 2026-07-02. Weighing against that: Negative session, down 1.0%; High volume 5.1x on decline — distribution signal. Wall Street's consensus price target sits at $98.00, implying +12.5% upside from $87.09. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (55/100). With earnings roughly 42 days out, the next report is the most likely near-term test of the move.
MDT price reaction
MDT last traded at $87.09, down $0.88 (-1.00%) from the previous close of $87.97. The session traded on 5.1× average volume (extreme), so the move carried above-average conviction.
Bullish and bearish analyst opinions on Medtronic plc (MDT)
The consensus analyst price target on Medtronic plc (MDT) is $98.00, 12.5% above the recent $87.09. Over the past 90 days analysts logged 1 upgrade, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDT line up.
The bullish case
- Wall Street's consensus price target of $98.00 implies +12.5% upside from $87.09.
- The Street's most bullish target is $115.00 (+32.0%).
- 1 analyst upgrade in the past 90 days, most recently UBS to Buy (2026-07-28).
- Medtronic plc (MDT) moved +5.04% from $79.20 to $83.19 on 2026-07-02.
The bearish case
- The most bearish analyst target is $83.00 (-4.7%).
- Negative session, down 1.0%.
- High volume 5.1x on decline — distribution signal.
- Medtronic traded slightly lower, down 0.25% to $86.22, as the market consolidates following regulatory wins and a pending corporate transaction.
- Medtronic fell 0.42% to $85.93 on elevated intraday volume (2.98x normal for this time of day), despite positive regulatory news: the FDA cleared and CE Mark approved the company's latest Affera™ Prism-2 Mapping Software and PulseSelect ProxBox™ Adapter for cardiac ablation procedures, announced September 30 via PR Newswire.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 6, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MDT
Frequently asked questions about MDT
Why did Medtronic plc (MDT) stock move?
MDT fell 1.0% to $87.09. The move is associated with company news.
How much did MDT stock fall?
MDT lost 1.00% ($0.88) versus the prior close of $87.97, last trading at $87.09 on 5.1× average volume.
When is Medtronic plc's next earnings date?
MDT's next earnings report is estimated for 2026-11-17 — about 42 days away.
What is the analyst price target for MDT?
The consensus analyst price target for MDT is $98.00, about 12.5% above the current $87.09. Over the past 90 days, analysts recorded 1 upgrade, 14 maintains, and 0 downgrades.
How BestStocks tracks MDT
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for MDT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 6, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.